Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
Integrating services works to curb HIV transmission from mothers to their infants and retain mothers in care, study shows
The following is a guest post by Emily Bobrow, PhD, of MEASURE Evaluation A combination of integrated service delivery approaches for mothers who are living with […]
Combatting MDR TB: Year three – Released four years ago, the federal National Action Plan for Combating Multidrug-Resistant Tuberculosis raised hopes that targets and strategies would […]
This year marks the close of a dynamic decade in global infectious disease research and responses that changed expectations of what humanity can accomplish toward making […]
2019 nCoV: With quarantines, novel coronavirus brings new and existing public health preparedness needs to the forefront
The following is a guest post by Jeffrey Duchin, MD, FIDSA The quarantine and travel restrictions announced by the US federal government in response to the […]